| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S19462 R82976 |
Straub (Controls exposed to LTG) (Phenobarbital) (Epilepsy), 2026 | Coordination disorders - ICD-10 codes: F82 - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick | Adjustment: No | 0.21 [0.01;3.51] C | 0/249 30/3,273 | 30 | 249 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16791 R70477 |
Thomas b (Phenobarbitone) (Epilepsy) (Controls exposed to LTG), 2022 | Delayed motor development quotient (< 84, i.e one SD of the mean) - The developmental assessment scale for Indian infants (DASII) - Between 12-24 months of age (mean (SD): 15.3 (3.9) months)) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
5.51 [0.69;43.95] C excluded (control group) |
15/83 1/26 | 16 | 83 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16792 R70478 |
Thomas b (Phenobarbitone) (Epilepsy) (Controls unexposed, sick), 2022 | The motor development quotient (MODQ) - The developmental assessment scale for Indian infants (DASII) - Between 12-24 months of age (mean (SD): 15.3 (3.9) months)) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 1.36 [0.81;2.29] | -/83 -/110 | - | 83 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9559 R33805 |
Shankaran (Phenobarbital) (Other indications), 2002 | The psychomotor developmental index ≤84 (PDI) (Bayley) | days before delivery excluded | randomized controlled trial | unexposed, sick | Adjustment: Randomisation |
0.79 [0.51;1.22] C excluded (exposition period) |
59/206 61/181 | 120 | 206 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9590 R33958 |
Koch (Phenobarbital or Primidone), 1996 | Minor neurological dysfunction (at age 6) (Touwen) | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 1.15 [0.19;7.11] C | 2/15 4/34 | 6 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.27 [0.78;2.08] | 36 | 347 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls exposed to LTG) (Phenobarbital) (Epilepsy; 2: Phenobarbitone) (Epilepsy) (Controls unexposed, sick; 3: Phenobarbital or Primidone;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 16791